Literature DB >> 15158465

Identifying gp85-regions involved in Epstein-Barr virus binding to B-lymphocytes.

Mauricio Urquiza1, Jorge Suarez, Ramses Lopez, Erika Vega, Helena Patino, Javier Garcia, Manuel A Patarroyo, Fanny Guzman, Manuel E Patarroyo.   

Abstract

Epstein-Barr virus lacking glycoprotein gp85 cannot infect B-cells and epithelial cells. The gp85 belongs to the molecular complex required for virus invasion of B-lymphocyte or epithelial cells. Moreover, there is evidence that gp85 is necessary for virus attachment to epithelial cells. Thirty-six peptides from the entire gp85-sequence were tested in epithelial and lymphoblastoid cell line binding assays to identify gp85-regions involved in virus-cell interaction. Five of these peptides presented high binding activity to Raji, Ramos, P3HR-1, and HeLa cells, but not to erythrocytes; Raji-cell affinity constants were between 80 and 140nM. Of these five peptides, 11435 ((181)TYKRVTEKGDEHVLSLVFGK(200)), 11436 ((201)TKDLPDLRGPFSYPSLTSAQ(220)), and 11438 ((241)YFVPNLKDMFSRAVTMTAAS(260)) bound to a 65kDa protein on Raji-cell surface. These peptides and antibodies induced by them (recognising live EBV-infected cells) inhibited Epstein-Barr virus interaction with cord blood lymphocytes. It is thus probable that gp85-regions defined by peptides 11435, 11436, and 11438 are involved in EBV invasion of B-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158465     DOI: 10.1016/j.bbrc.2004.04.177

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion.

Authors:  Austin N Kirschner; Amanda S Lowrey; Richard Longnecker; Theodore S Jardetzky
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

2.  α-Helix peptides designed from EBV-gH protein display higher antigenicity and induction of monocyte apoptosis than the native peptide.

Authors:  Mauricio Urquiza; Johanna Melo-Cardenas; Tatiana Guevara; Ignacia Echeverria; Isabel C Rodriguez; Magnolia Vanegas; Mario Amzel; Manuel E Patarroyo
Journal:  Amino Acids       Date:  2010-05-16       Impact factor: 3.520

3.  Identifying putative Mycobacterium tuberculosis Rv2004c protein sequences that bind specifically to U937 macrophages and A549 epithelial cells.

Authors:  Martha Forero; Alvaro Puentes; Jimena Cortés; Fabio Castillo; Ricardo Vera; Luis E Rodríguez; John Valbuena; Marisol Ocampo; Hernando Curtidor; Jaiver Rosas; Javier García; Gloria Barrera; Rosalba Alfonso; Manuel A Patarroyo; Manuel E Patarroyo
Journal:  Protein Sci       Date:  2005-09-30       Impact factor: 6.725

4.  Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: potential TB vaccine candidate antigen.

Authors:  Diana P Cifuentes; Marisol Ocampo; Hernando Curtidor; Magnolia Vanegas; Martha Forero; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  BMC Microbiol       Date:  2010-04-13       Impact factor: 3.605

5.  Comparative pathobiology of macaque lymphocryptoviruses.

Authors:  Angela Carville; Keith G Mansfield
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

6.  Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.

Authors:  Rui-Chen Li; Yong Du; Qiu-Yao Zeng; Lin-Quan Tang; Hua Zhang; Yan Li; Wan-Li Liu; Qian Zhong; Mu-Sheng Zeng; Xiao-Ming Huang
Journal:  Oncotarget       Date:  2016-03-29

7.  Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.

Authors:  Bingchun Zhao; Xiao Zhang; Claude Krummenacher; Shuo Song; Ling Gao; Haojiong Zhang; Miao Xu; Lin Feng; Qisheng Feng; Musheng Zeng; Yuting Xu; Yixin Zeng
Journal:  Front Immunol       Date:  2018-05-01       Impact factor: 7.561

8.  A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.

Authors:  Xiao Zhang; Bingchun Zhao; Mingmei Ding; Shuo Song; Yinfeng Kang; Yang Yu; Miao Xu; Tong Xiang; Ling Gao; Qisheng Feng; Qinjian Zhao; Mu-Sheng Zeng; Claude Krummenacher; Yi-Xin Zeng
Journal:  Theranostics       Date:  2020-04-27       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.